JP2022510097A - Composition for hair loss or skin inflammation suppression - Google Patents

Abstract

The present invention relates to a composition for suppressing hair loss or skin inflammation, and is one or more selected from the group composed of amentoflavone, Kashiwakojin extract, genistein and Biochanin A. Including the ingredients of.

Description

This application claims the benefit of priority under Korean Patent Application No. 10-2018-01050304 dated November 29, 2018, and all the contents disclosed in the literature of the relevant Korean patent application are part of this specification. Included as a part.

The present invention relates to a composition for suppressing hair loss or skin inflammation having a PTGDS (prostaglandin D2 syncase) activity suppressing effect, and more particularly, amentoflavone and; Kashiwakojin extract, genistein and biochanin A. The present invention relates to a composition containing one or more components selected from the group composed of (Biochanin A) and suppressing hair loss or skin inflammation through an excellent PTGDS activity suppressing effect.

In general, the causes of hair loss include genetic factors, drug administration, aging progression, radiation therapy, post-severe illness stress and the like. From a biochemical and physiological point of view, the hair loss phenomenon is known to be due to overactivity, scalp blood circulation problems, and deficiency of nutrients essential for hair metabolism. These factors alone or in combination accelerate alopecia and make the symptoms worse. In particular, genetic or acquired factors over-operate androgen production, alteration, recognition and signaling, increasing the likelihood of alopecia worsening if the hair follicle structure ages prematurely.
Various methods have been tried to treat hair loss, but surgical methods include scalp reconstruction, scalp shaping by hair loss site reduction and tissue dilation, and self-hair transplantation. Although the surgical treatment method has an excellent effect, it has a disadvantage that it is difficult to be widely used because the financial and mental burden on the patient is very large.
In addition, various therapeutic agents are used, but since minoxidil, which is a typical external preparation, has a capillary dilation function, it can be applied to the scalp to prevent hair loss, but it has side effects such as itching and irritation. There is a problem that the active target in hair loss treatment has not been clarified yet. Finasteride, which is an internal medicine, has an inhibitory effect on the production of the male hormone DHT (5α-dihydrotestosterone) that induces hair loss, and it is known that the effect of suppressing hair growth or hair loss appears when taken for about 6 months to 1 year. Has been done. However, there is a problem that if the drug is stopped, it returns to the original state within 2 months, and it is known that side effects such as reproductive dysfunction may occur.
Therefore, there is a demand for the development of a hair loss inhibitor that has no side effects, is harmless to the human body, and has a continuous hair loss inhibitory effect.
PTGDS is an enzyme that produces Prostaglandin D2 (PGD2), and PGD2 has been shown to be present at higher levels in the scalp of men with alopecia than in the scalp of men without alopecia. , Known as an important factor causing hair loss (Garza et al. (2012) Sci. Transl. Med. 4, 126 ra34). In addition, it was revealed that PTGDS regulates the inflammatory response through PGD2 (R. Rajakariar et al., PNAS, 2007, 104, 20979-20984), suppresses the activity of PTGDS as a mediator of the inflammatory response, and suppresses the inflammatory response. Can be inhibited.

Korean Registered Patent No. 10-1766752 (Pharmaceutical Composition Containing Minoxidil) Korean Published Patent No. 10-2015-0046332 (polymerized finasteride nanoparticles, aqueous composition containing the same, composition for hair loss treatment, and its manufacturing process and its use).

In order to solve the above-mentioned problems, the present inventors have an object to provide a composition which has few side effects due to continuous use and effectively suppresses hair loss and skin inflammation.

The present inventors have completed the present invention by confirming that by suppressing the activity of PTGDS, the inflammatory reaction on the skin can be suppressed and at the same time, the hair loss reaction can be suppressed.
In order to achieve the above object, the composition for suppressing hair loss or skin inflammation according to one embodiment of the present invention is one or more selected from the group composed of amentoflavone and Kashiwakojin extract, genistein and biochanin A. Contains the ingredients of.
The amentoflavone can be contained in an amount of 0.1 to 1,000 ppm based on the total weight of the composition. Amentoflavone may be extracted from one or more selected from the group consisting of Selaginella, Selaginella, Selaginella, Makikashiwa, Kashiwa and Ginkgo.
The Kashiwakojin extract can be contained in an amount of 10 to 10,000 ppm based on the total weight of the composition.
Genistein can be contained in an amount of 1 to 1,000 ppm based on the total weight of the composition. Genistein can be extracted from one or more selected from the group composed of beans and isoflavones.
The biochanin A can be contained in an amount of 10 to 1,000 ppm based on the total weight of the composition. Biochanin A can be extracted from one or more selected from the group composed of Acronychia vulgaris, beans, red clover and isoflavones.
The composition can suppress the activity of PTGDS in vivo. The composition for suppressing hair loss or skin inflammation contains a cosmetic, and the dosage form of the cosmetic can be selected from solutions, creams, lotions, shampoos, hair tonics, sprays and gels.
The composition for suppressing hair loss or skin inflammation can be administered to the human body through transdermal injection or subcutaneous injection, and either an external skin preparation agent or an oral administration agent may be selected.
The skin includes hair follicles and scalp.

The composition provided by the present invention suppresses hair loss or skin inflammation by including amentoflavone in one or more components selected from the group composed of Kashiwakojin extract, genistein and biochanin A. A synergistic effect can be obtained. In addition, the composition for suppressing hair loss or skin inflammation of the present invention can be used for a long period of time using a natural substance and has no side effects.

It is a result graph which shows the effect of suppressing PGD2 production of PTDGS enzyme by one Example of this invention through an ELISA method.

Hereinafter, the present invention will be described in more detail in order to facilitate understanding of the present invention.
In the present invention, the enzyme flavone used as an active ingredient has an antioxidant effect (Mora A. et al., Biochem. Pharmacol., 40 (4), pp793-7, 1990) and suppresses phosphodiesterase. Action (Lee SJ. et al., Life Sci., 57 (6), pp551-558, 1995), Phospholipase C-γ1 enzyme activity inhibitory action (Lee HS. Et al., Planta. Med., 1996) , 62 (4), pp293-296), anti-HIV action, anti-inflammatory action by suppressing cyclooxygenase and lipoxygenase (Kim HP. et al., Prostaglandins LeukotSent) ), Pp17-24, 1998), cAMP-phosphodiesterase inhibitory action, antibiotic action against virus, antibacterial action, etc. were studied (Kim HK. et al., Arch. Pharm. Res., 21 (4). ), Pp406-410, 1998; Lin YM. et al., Pranta. Med., 65 (2), pp120-125, 1999; Krause-Baranowska M. et al., Pranta. Med., 65 (6), pp572-573, 1999).

Amentoflavone can be extracted from one or more selected from the group consisting of Selaginella, Selaginella, Selaginella, Makikashiwa, Kashiwa and Ginkgo. Selaginella is a perennial plant belonging to the family Selaginella, which grows within 5 to 20 cm, and the rhizomes derived underneath are very hard and short, and are characterized by many beard roots. Selaginella is a vascular plant belonging to the family Selaginella, which is characterized by extending on rocks, rhizomes extending in the soil and between bryophytes, and the tips growing straight. Makikashiwa belongs to the family Selaginella, and is a cryptogam that lives by sticking to rocks. It is named because it becomes a fist when dried. Hinoki cypress is an evergreen cypress tree of the family Oriental Arbor-vitae, and its leaves are obovate or oval, and both sides are green or pale yellowish green. Ginkgo is a deciduous tree of the Ginkgoaceae family, and its leaves are fan-shaped and split in two at the center.

Amentoflavone is represented by the following chemical formula 1.
<Chemical 1>

The Thujae semen used as an active ingredient in the present invention is a seed of Oriental Arbor-vitae (Curpressaceae), which is long oval or long cylindrical in an oval shape. .. Kashiwako Hitoshi is known to allow the mustache and hair that have fallen out of the Sansho plaster prescription of the Tohoku Ihokan to grow again. It is included in the prescription used when aging symptoms appear. In terms of modern science, two animal models have shown high hair growth activity, and it has been proved that it is used as a useful substance for alopecia by regulating androgen conversion.

In the present invention, for example, the Kashiwakojin extract can be produced by the following method. Kashiwakojin is extracted with 2 times volume of 95% ethanol, filtered and concentrated, and then 5 times volume of water and 5 times volume of ethyl acetate are added and shaken to separate the layers. Moisture in the ethyl acetate layer is removed using magnesium sulfate, filtered and concentrated to obtain Kashiwakojin extract.

Genistein, which is used as an active ingredient in the present invention, promotes the replication of normal cells as well as a strong antioxidant effect, anti-inflammatory effect, and anticancer effect as an estrogen analog of the plant kingdom. An SCI-class clinical paper has been published as a component that suppresses hair loss, and recently clinical results have been reported as a substance that suppresses photoaging. In one embodiment, it has a hormonal effect as an estrogen analog of genistein, a cell regeneration effect, a photoaging inhibitory effect, a hair loss inhibitory effect, and an action of promoting hair growth. Genistein, which is a kind of polyphenol, can be separated and extracted from, for example, soybean isoflavone, but is not limited thereto.

Genistein is represented by the following chemical formula 2.
<Chemical 2>

Biochanin A used as an active ingredient in the present invention can be separated from, for example, one or more selected from the group composed of, for example, Acronychia vulgaris, beans, red clover and isoflavones, but is not limited thereto. ..

Biochanin A is represented by the following chemical formula 3.
<Chemical 3>

In one embodiment of the present invention, one or more components selected from the group further composed of Kashiwakojin extract, genistein and biochanin A as compared with the composition containing amentoflavone as a single active ingredient. It was confirmed that the effect of suppressing PTGDS activity was further excellent when the combination was included.
That is, the present invention provides a composition capable of effectively suppressing the activity of PTGDS, reducing the production of PGD2, which is an element that causes hair loss, suppressing the hair loss reaction, and suppressing the inflammatory reaction generated in the skin. do.

In one embodiment of the invention, the composition may be used in a pharmaceutical composition.
The pharmaceutical composition comprises an active ingredient containing amentoflavone and one or more components selected from the group composed of Kashiwakojin extract, genistein and biochanin A, as well as preservatives, stabilizers and hydration agents. It may further contain an agent or an emulsifying agent, a pharmacological adjunct such as a salt and / or a buffer for osmotic pressure regulation, and other therapeutically useful substances, and various oral administrations or preparations by conventional methods. It can be formulated in the form of a parenteral administration.

Examples of the oral administration agent include tablets, pills, hard and soft capsules, liquids, suspending agents, emulsifiers, syrups, powders, powders, fine granules, granules, pellets and the like. In addition to the active ingredient, the form is a surfactant, a diluent (eg, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), a lubricant (eg, silica, talc, stearic acid and its magnesium or calcium salt and polyethylene). Glycol) can be included. Tablets can further contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacant, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally disintegrating such as starch, agar, alginic acid or sodium salts thereof. Pharmaceutical additives such as agents, absorbents, colorants, flavors and sweeteners can be included. The tablets can be produced by conventional mixing, granulation or coating methods.

Further, the form of parenteral administration may be a transdermal, subcutaneous, intravenous or intramuscular dosage form, for example, an injection, a drip, an ointment, a lotion, a gel, a cream, a spray, a suspension, etc. Dosage forms such as emulsions, suppositories, patches, etc. are, but are not limited to.

The dose determination of the active ingredient is within the standard of a normal technician, and the daily dose of the drug depends on various factors such as the degree of progression of the subject to be administered, the time of onset, age, health condition, complications, etc. On one side, the composition can be administered in an amount of 1 μg / kg to 200 mg / kg, and on the other side, 50 μg / kg to 50 mg / kg can be administered in divided doses 1 to 3 times a day. This dose does not limit the scope of the invention in any way.

The pharmaceutical composition may be an external preparation for skin, and the external preparation for skin is a general term including anything applied outside the skin, and includes various dosage forms of pharmaceutical products.
In one embodiment of the invention, the composition may be used in a cosmetic composition. The cosmetic composition may further contain functional additives and components contained in general cosmetic compositions, in addition to the eruption of Lactococcus lactis W-camellia strain. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, sphingolipids and seaweed extracts. Other compounding ingredients include milk fat ingredients, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, bactericides, antioxidants, plant extracts, etc. Examples include pH adjusters, alcohols, pigments, fragrances, blood circulation promoters, cooling sensitizers, antiseptic agents, purified water and the like.

The dosage form of the cosmetic composition is not particularly limited, and it can be appropriately selected depending on the intended purpose. For example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutritional lotion, massage cream, nutritional cream, moisture cream, hand cream, foundation, essence, nutritional essence, pack, soap, cleansing. It may be produced in any one or more dosage forms selected from the group consisting of foams, cleansing lotions, cleansing creams, body lotions and body cleansers, but is not limited thereto.

In addition, the cosmetic composition may be formulated containing a dermatologically or dermatologically acceptable medium or base. It has all dosage forms suitable for topical application, such as solutions, gels, solids, anhydrous products, emulsions obtained by dispersing the oil phase in the aqueous phase, suspensions, microemulsions, microcapsules, microgranule. It may be provided in the form of spheres or ionic (lipolips) and nonionic follicular dispersants, or in the form of creams, skins, lotions, powders, ointments, sprays or concealed sticks. It may also be used in the form of foam or in the form of an aerosol composition further comprising a compressed propellant. These compositions can be produced by conventional methods in the art.

Further, the cosmetic composition may be used in a composition for scalp or hair. Therefore, the cosmetic composition is a formulation used together with the scalp and hair, for example, shampoo, conditioner, scalp treatment, hair treatment, scalp hair combined treatment, hair loss prevention hair treatment, damaged hair treatment, leave. -In) It can be formulated into scalp or hair, scalp and hair products such as conditioner, wash-off conditioner or hair essence.

When the dosage form of the present invention is a paste, cream or gel, the carrier components include animal fiber, plant fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc or zinc oxide. Can be used.

When the dosage form of the present invention is powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be utilized as carrier components, and especially in the case of spray, chlorofluorohydrocarbon, It can include propellants such as propane / butane or dimethyl ether.

When the dosage form of the present invention is a solution or emulsion, a solvent, solvent or emulsion can be used as the carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl. Examples include alcohols, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.

When the dosage form of the present invention is a suspension, the carrier components include water, liquid phase diluents such as ethanol or propylene glycol, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters. Suspensions, microcrystalline cellulose, aluminum metahydroxydo, bentonite, agar or tracant, etc. can be utilized.

When the dosage form of the present invention is cleansing containing a surfactant, fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuccinic acid monoester, icethionic acid, imidazolinium derivative, methyl taurine, sarcosin, fatty acid amide are used as carrier components. Ether sulfate, cocamidopropyl betaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative, ethoxylated glycerol fatty acid ester and the like can be utilized.

The composition according to one embodiment of the present invention may contain dyes, preservatives, sequestrants, fragrances and the like within the range of maintaining stability.

Hair loss or skin inflammation suppression method The present invention also relates to a hair loss or skin inflammation suppression method. The method for suppressing hair loss or skin inflammation includes a step of applying the above-mentioned composition for suppressing hair loss or skin inflammation to a subject having hair loss or skin inflammation. The method for suppressing hair loss or skin inflammation may mean a method for preventing, ameliorating and / or treating hair loss or skin inflammation.
The composition for suppressing hair loss or skin inflammation may be applied by being applied to the skin, and preferably, the scalp where the hair loss phenomenon is worried or the hair loss phenomenon appears, or the scalp where the hair loss phenomenon is worried or inflammation appears. It may be applied to the skin. When the composition is applied to the face, it is more advantageous to obtain mental and physical stability from the scent of yuzu oil bead and to take a deep sleep.
In addition, the composition for suppressing hair loss or skin inflammation may be applied to the scalp or skin once a day. An element in which the combination of amentoflavone contained in the composition and one or more components selected from the group composed of Kashiwakojin extract, genistein and biochanin A suppresses the activity of PTGDS and causes hair loss. It is advantageous for hair loss or suppression of skin inflammation by reducing the production of PGD2, which suppresses the hair loss reaction, and suppresses the inflammatory reaction generated in the skin.
In addition, the composition for suppressing hair loss or skin inflammation can show a more improved effect of suppressing hair loss or skin inflammation when applied to the skin once a day for 3 to 8 weeks. The composition for suppressing hair loss or skin inflammation shows an excellent hair loss or skin inflammation suppressing effect even when applied to the skin once a day, and is usually used continuously for 3 weeks or more, preferably 3 to 8 weeks. At times, it exhibits a very good hair loss or skin inflammation inhibitory effect.
The single application amount of the composition for suppressing hair loss or skin inflammation varies depending on the condition of the subject experiencing hair loss or skin inflammation, the degree of sleep disorder, the application area and the form of the composition, but is usually 25 mg to 150 mg. It can be appropriately adjusted and applied within the range of the one-time application amount.

Hereinafter, the present invention will be described in more detail with reference to examples. It can be said to those skilled in the art that these examples are intended to illustrate the present invention and that the scope of the invention is not construed as being limited by these examples.

<Examples> Production of composition for suppressing hair loss or skin inflammation <Examples 1 to 3>
To 1000 ml of purified water, in addition to amentoflavone, one or more components selected from the group composed of Kashiwakojin extract, genistein and biochanin A were added, and then the mixture was stirred. The specific contents of the active ingredient are shown in Table 1.

<Comparative Examples 1 to 4>
The compositions of Comparative Examples used the same active ingredients used in Examples 1 to 3 alone, but were produced so that the component content was 10 times higher. Specifically, one of amentoflavone, Kashiwakojin extract, genistein and biochanin A is added to 1000 ml of purified water, and then the mixture is stirred. The specific contents of the active ingredient are shown in Table 1.

<Test Example> PTGDS activity inhibitory effect (ELISA assay)
Prostaglandin H2 (PGH2), which is a substrate for an enzymatic reaction, is treated with PTGDS to produce prostaglandin D2 (PGD2), but after the compositions produced in Examples 1 to 3 are added together. , The amount of decrease in PGD2 production was measured to confirm the effect of suppressing PTGDS activity.
The amount of PGD2 produced was measured by an enzyme-linked immunosorbent assay (ELISA). The enzyme-linked immunosorbent assay (ELISA) was carried out in the following steps.
(A) Step of coating the surface of the solid substrate with Examples 1 to 3
(B) A step of reacting PTGDS with the PGH2,
(C) The step of reacting the result of the step (b) with the secondary antibody to which the enzyme is bound, and (d) the step of showing the activity of the enzyme through an absorbance measurement at 410 nm with an ELISA reader are included.

Suitable solid substrates are hydrocarbon polymers (eg, polystyrene and polypropylene), glass, metals or gels, most preferably microtiter plates. Enzymes bound to the secondary antibody include, but are not limited to, enzymes that catalyze color-developing, fluorescent, luminescent or infrared reactions, such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, luciferase. And cytochrome P450. When alkaline phosphatase is used as the enzyme that binds to the secondary antibody, bromochloroindolyl phosphate (BCIP), nitroblue tetrazolium (NBT), and naphthol-ASB1-phosphate (naphthol-AS-B1) are used as substrates. -When color reaction substrates such as phosphate) and ECF (enhanced chemifluorescence) are utilized and horseradish peroxidase is utilized, chloronaphthol, aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin (bis-N-nitrate). Methylacrydinium), Resolvinbenzyl Ether, Luminol, Armfrec Red Reagent (10-Acetyl-3,7-Dihydroxyphenoxazine), TMB (3,3,5,5-tetramethylbenzidine), ABTS (2,2' Substrate such as -Azine-di [3-ethylbenzthiazoline sulphonate]) and o-phenylenediamine (OPD) may be utilized.

As a result of the analysis, as shown in FIG. 1, in Examples 1 to 3 of the present invention, the amount of PGD2 produced was reduced as compared with Comparative Examples 1 to 4 in which the component content was 10 times higher. Therefore, through the above results, the present inventors combine amentoflavone with one or more components selected from the group composed of Kashiwakojin extract, genistein and biochanin A to obtain the above-mentioned component substance. It was found that the ability to suppress PTGDS activity was superior to that when used alone.

Dosage forms of the composition according to one embodiment of the present invention will be described below, but other than these dosage forms, various dosage forms can be applied, and this is merely for exemplifying the present invention. , The scope of the invention is not limited by these dosage form examples.

<Dosage Form Example 1> Tablets After mixing 100 mg of the composition, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate produced by Examples 1 to 3 of the present invention, tablets are tableted according to a usual method for producing tablets. Made tablets.
<Dosage Form Example 2> Capsule After mixing 100 mg of the composition, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate produced by Examples 1 to 3 of the present invention, gelatin is prepared according to a usual method for producing a capsule. Capsules were filled to produce capsules.
<Dosage Form Example 3> Granules 50 mg of the composition produced according to Examples 1 to 3 of the present invention, 250 mg of anhydrous crystalline glucose and 550 mg of starch are mixed, molded into granules using a fluidized bed granule machine, and then a bag. Filled with.
<Formation Example 4> Drinking agent After mixing 50 mg of the composition produced according to Examples 1 to 3 of the present invention, 10 g of glucose, 0.6 g of citric acid and 25 g of liquid phase oligosaccharide, 300 ml of purified water is added to each. The bottles were filled with 200 ml each and then sterilized at 130 ° C. for 4 to 5 seconds to produce a drink.

<Dosage Form Example 5> Injection An injection was produced by a usual method according to the composition shown in Table 2.

<Dosage form example 6> Soft lotion (skin lotion)
A soft lotion was produced by a usual method according to the composition shown in Table 3 below.

<Dosage form example 7> Nutritional lotion (milk lotion)
A nutritional lotion was produced by a conventional method according to the composition shown in Table 4.

<Dosage Form Example 8> Massage Cream A massage cream was produced by a usual method according to the composition shown in Table 5.

<Dosage Form Example 9> Production of Hair Lotion A hair lotion was produced by a usual method with the composition shown in Table 6.

<Dosage Form Example 10> Production of shampoo composition A shampoo composition was produced by a usual method with the composition shown in Table 7.

<Dosage Form Example 11> Production of Hair Treatment A hair treatment was produced by a usual method with the composition shown in Table 8.

Claims (15)

With Amentoflavone,
A composition for hair loss or skin inflammation suppression, which comprises one or more components selected from the group composed of Kashiwakojin extract, Genistein and Biochanin A; The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the amentoflavone is contained in an amount of 0.1 to 1,000 ppm based on the total weight of the composition. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the amentoflavone is extracted from one or more selected from the group composed of selaginella, selaginella, selaginella, cypress, ginkgo and ginkgo. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the Kashiwakojin extract is contained in an amount of 10 to 10,000 ppm based on the total weight of the composition. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the genistein is contained in an amount of 1 to 1,000 ppm based on the total weight of the composition. The composition for hair loss or skin inflammation suppression according to claim 1, wherein the genistein is extracted from one or more selected from the group composed of beans and isoflavones. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the biochanin A is contained in an amount of 10 to 1,000 ppm based on the total weight of the composition. The composition for hair loss or skin inflammation suppression according to claim 1, wherein the biochanin A is extracted from one or more selected from the group composed of Acronychia vulgaris, beans, red clover and isoflavone. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the composition suppresses the activity of PTGDS (Prostagradin D2 Synthase) in vivo. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the composition for suppressing hair loss or skin inflammation is a cosmetic. The composition for hair loss or skin inflammation suppression according to claim 10, wherein the dosage form of the cosmetic is selected among solutions, creams, lotions, shampoos, hair tonics, sprays and gels. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the composition for suppressing hair loss or skin inflammation is administered to the human body through transdermal injection or subcutaneous injection. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the composition for suppressing hair loss or skin inflammation is an external skin preparation agent or an orally administered agent. The composition for suppressing hair loss or skin inflammation according to claim 1, wherein the skin includes hair follicles and a scalp. A method for suppressing hair loss or skin inflammation using the composition according to any one of claims 1 to 14.

Images